Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
BMC Nephrol ; 12: 68, 2011 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-22171968

RESUMEN

BACKGROUND: Acute pyelonephritis (APN) is differently defined according to imaging or clinical criteria. In adults information on the relationship between imaging and clinical data is lacking.Our study was aimed at analysing the relationship between the clinical and imaging presentation of APN, defined according to imaging criteria (parenchymal involvement at MR or CT scan). METHODS: All consecutive patients hospitalized for "non-complicated" APN were considered (June 2005-December 2009). Clinical, biochemical and imaging data at hospitalization were analyzed by univariate and logistic regression analysis. RESULTS: There were 119 patients, all females, median age 32 years (15-72). At hospitalization, inflammatory markers were elevated (CRP median: 12.1 mg/dL, normal < 0.8). Incomplete presentations were frequent: fever was absent in 6.7%, pain in 17.8%, lower urinary tract symptoms in 52.9%. At CT or MR scan the lesions were bilateral in 12.6%, multiple in 79.8%; abscesses were present in 39.5%. Renal scars were found in 15.1%. Positive cultures were correlated with multiple foci (multivariate OR 4.2; CI 1.139-15.515). No other sign/symptom discriminated between small lesions, abscesses or multifocal involvement. CONCLUSIONS: APN is a protean disease. In the absence of strict correlation with clinical or biochemical markers, imaging studies are required to assess the severity of kidney involvement.


Asunto(s)
Riñón/diagnóstico por imagen , Riñón/patología , Imagen por Resonancia Magnética/métodos , Pielonefritis/diagnóstico , Tomografía Computarizada por Rayos X/métodos , Enfermedad Aguda , Adolescente , Adulto , Anciano , Humanos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Adulto Joven
3.
Ital J Pediatr ; 37: 20, 2011 May 12.
Artículo en Inglés | MEDLINE | ID: mdl-21569394

RESUMEN

Hereditary hyperferritinemia cataract syndrome (HHCS) is a rare condition caused by mutations in the gene coding for the light chain of ferritin; it does not lead to iron overload, but it is associated with the risk of developing a bilateral nuclear cataract also in childhood. On the contrary, a raise of serum ferritin levels is a common finding in pediatrics. We describe here a case of HHCS that offers some interesting clues for the daily practice. Our patient is a 6 year old Italian boy who came to our attention after some time of diagnostic uncertainties because of persistently high levels of ferritin with no apparent cause. We were guided to the suspect of this syndrome by the family history (5 members with various degrees of cataract developed in first infancy). High levels of serum ferritin and specific genetic testing (mutation A37C) confirmed the diagnosis. This case underlines the need of considering rare genetic syndromes, including hereditary hyperferritinemia cataract syndrome, in the differential diagnosis of raised serum ferritin in children and the importance of paying attention to family history in considering a patient with isolated raised levels of serum ferritin.


Asunto(s)
Catarata/congénito , ADN/genética , Ferritinas/sangre , Predisposición Genética a la Enfermedad , Pruebas Genéticas/métodos , Antígenos de Histocompatibilidad Clase I/genética , Trastornos del Metabolismo del Hierro/congénito , Proteínas de la Membrana/genética , Mutación , Catarata/sangre , Catarata/diagnóstico , Catarata/genética , Niño , Análisis Mutacional de ADN , Diagnóstico Diferencial , Proteína de la Hemocromatosis , Heterocigoto , Humanos , Trastornos del Metabolismo del Hierro/sangre , Trastornos del Metabolismo del Hierro/diagnóstico , Trastornos del Metabolismo del Hierro/genética , Masculino , Linaje
4.
Ann N Y Acad Sci ; 1202: 75-8, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20712776

RESUMEN

Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion-dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis. The last requires close monitoring of blood count and precludes the use of DFP in conditions with bone marrow abnormalities. The efficacy profile is similar among the three available chelators. For DFP, the choice of dosage is crucial to optimize the effect on liver iron concentration, according to the iron load degree and transfusional iron input. Growing evidence indicates that DFP, alone or in combination with deferoxamine, is effective in removing cardiac iron and preventing cardiac iron load. The available data consolidate an important role of DFP in the management of iron overload. There is a need to compare directly the relative value of the available chelators in the long-term prevention of iron toxicity by well-designed randomized controlled trials.


Asunto(s)
Quelantes del Hierro/uso terapéutico , Piridonas/uso terapéutico , Talasemia/tratamiento farmacológico , Deferiprona , Deferoxamina/uso terapéutico , Humanos , Hierro/metabolismo , Hígado/metabolismo , Ensayos Clínicos Controlados Aleatorios como Asunto , Reacción a la Transfusión
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...